Results for this period
Full year1 April 2025–31 March 2026ConsolidatedJapanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Research and development and clinical trial expenses were incurred ahead of revenue. Net sales and segment profit declined in the Research Support Business, while net sales declined and the Medical Business recorded a segment loss.
A disclosure regarding events or conditions that may cast significant doubt on the going concern assumption is included. While the Company continues to incur operating losses because research and development and clinical trial expenses are incurred ahead of revenue, its financial base is stable and it aims to achieve profitability at an early stage. The notes on the going concern assumption state, “Not applicable.”
| Item | Details |
|---|---|
| Fiscal Period Classification | Full year |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2025–31 March 2026 |
| Net Sales | ¥2,233 million (YoY -25.0%) |
| Operating profit | ¥-860 million |
| Ordinary income | ¥-581 million |
| Profit attributable to owners of the parent | ¥-591 million |
| Net income per share | -¥6.25 |
| Operating Margin | -38.5 |
| Equity ratio | End of the current fiscal period 91.7 / End of previous period 92.9 |
| Total assets | ¥9,652 million |
| Net assets | ¥8,846 million |
| Cash flows from operating activities | ¥-383 million |
| Cash flows from investing activities | ¥57 million |
| Cash flows from financing activities | ¥0 million |
| Cash and cash equivalents at end of period | ¥2,603 million |
| Full-year earnings forecast | Net Sales ¥2,629 million (YoY +17.7%) / Operating profit ¥-630 million / Ordinary income ¥-458 million / Net income ¥-458 million |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Shareholder Return Policy | The Company does not plan to pay dividends for the time being (no numerical target stated) |
| Segment revenue | Research Support Business ¥1,952,479 thousand (YoY -19.1%), Medical Business ¥281,039 thousand (YoY -50.2%) |
| Segment profit | Research Support Business ¥96,523 thousand (YoY -84.5%), Medical Business ¥-43,905 thousand |
| Regional sales | ¥517,610 thousand, ¥1,189,341 thousand, ¥443,232 thousand, ¥83,334 thousand |
| Depreciation and amortization | ¥72,251 thousand |
| Impairment loss | Amount ¥6,055 thousand / Subject assets Not disclosed |
| Breakdown of extraordinary income (loss) | Extraordinary income No / Extraordinary loss Impairment Losses ¥6,055 thousand |
| Disclosure regarding the going concern assumption | A disclosure regarding events or conditions that may cast significant doubt on the going concern assumption is included. While the Company continues to incur operating losses because research and development and clinical trial expenses are incurred ahead of revenue, its financial base is stable and it aims to achieve profitability at an early stage. The notes on the going concern assumption state, “Not applicable.” |
| Change in accounting policy | Changes due to revisions to standards No / Other changes Yes (on the cover page; the notes state, “Not applicable.”) / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Not disclosed / Excluded Number of companies 2 / Company name Cell Innovation Partners, L.P., Cell Innovation Partners Ltd. |
| Material subsequent events | Not applicable. |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Not disclosed |
| Issued Shares at Period-End | 95,147,891 |
| Treasury Shares at Period-End | 117,256 |
| Factors Behind Changes in Business Performance | Research and development and clinical trial expenses were incurred ahead of revenue. Net sales and segment profit declined in the Research Support Business, while net sales declined and the Medical Business recorded a segment loss. |
Items this document does not state (3)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company explains that it continues to incur operating losses because research and development and clinical trial expenses for iPS cells, regenerative medicine products and other products are being incurred ahead of revenue, among other factors.